The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Lamb Weston Holdings, Inc. (LW)
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Lamb Weston Holdings, Inc. (LW)
The Law Offices of Frank R. Cruz reminds investors of the upcoming August 12, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Lamb Weston Holdings, Inc. (“Lamb Weston” or the “Company”) (NYSE: LW) common stock between July 25, 2023 and April 3, 2024, inclusive (the “Class Period”).
If you are a shareholder who suffered a loss, click here to participate.
On April 4, 2024, Lamb Weston disclosed that it had experienced significant challenges in its transition to its highly-touted new Enterprise Resource Planning (”ERP”) software system, causing the Company to lose $135 million in sales during the third quarter of fiscal 2024. Additionally, the Company lowered its sales guidance for the remainder of the full fiscal year by $330 million.
On this news, Lamb Weston’s stock price fell $19.59, or 19.4%, to close at $81.53 per share on April 4, 2024, thereby injuring investors.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants: (1) knew of, or recklessly disregarded, problems associated with the ERP system that would hinder its successful implementation; (2) pushed ahead with its implementation of an ERP system that was not ready to go live, knowing that a premature roll-out would have a material negative impact on the Company’s business and operations; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading
Follow us for updates on Twitter: twitter.com/FRC_LAW.
If you purchased or otherwise acquired Lamb Weston common stock during the Class Period, you may move the Court no later than August 12, 2024 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240809130845/en/
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks